Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor
- PMID: 24565585
- PMCID: PMC4159759
- DOI: 10.1053/j.seminoncol.2013.12.006
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor
Abstract
The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) gene in a subset of NSCLC patients. Several additional oncogenic mutations, including gene fusions and amplifications, have since been discovered, with a number of drugs that target each specific oncogene. This review focuses on oncogenes in NSCLC other than EGFR and their companion "targeted therapies." Particular emphasis is placed on the role of ALK, ROS1, RET, MET, BRAF, and HER2 in NSCLC.
Copyright © 2014 Elsevier Inc. All rights reserved.
Conflict of interest statement
Eamon Berge: no financial conflicts of interest to disclose.
Robert C. Doebele: Advisory board for Pfizer and Boehringer Ingelheim, research grants from Pfizer, Eli Lilly and ImClone, patent filed with USPTO for NTRK1 as a predictive biomarker.
Figures
Similar articles
-
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21. Clin Lung Cancer. 2020. PMID: 31839532
-
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038731 Review.
-
Management and future directions in non-small cell lung cancer with known activating mutations.Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857124 Review.
-
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. Int J Mol Sci. 2021. PMID: 33807876 Free PMC article. Review.
-
Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.Cancer Treat Rev. 2015 May;41(5):401-11. doi: 10.1016/j.ctrv.2015.03.009. Epub 2015 Mar 28. Cancer Treat Rev. 2015. PMID: 25842168 Review.
Cited by
-
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers.JCO Precis Oncol. 2022 Mar;6:e2100245. doi: 10.1200/PO.21.00245. JCO Precis Oncol. 2022. PMID: 35319967 Free PMC article.
-
Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience.Diagnostics (Basel). 2022 Feb 1;12(2):372. doi: 10.3390/diagnostics12020372. Diagnostics (Basel). 2022. PMID: 35204463 Free PMC article.
-
Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations.Curr Oncol. 2021 Nov 3;28(6):4432-4445. doi: 10.3390/curroncol28060376. Curr Oncol. 2021. PMID: 34898548 Free PMC article.
-
Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape.Cancers (Basel). 2021 Oct 16;13(20):5203. doi: 10.3390/cancers13205203. Cancers (Basel). 2021. PMID: 34680351 Free PMC article. Review.
-
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.Int J Mol Sci. 2021 Jan 14;22(2):792. doi: 10.3390/ijms22020792. Int J Mol Sci. 2021. PMID: 33466795 Free PMC article. Review.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
-
- Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907. - PubMed
-
- Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) Available from URL: http://seer.cancer.gov/csr/1975_2009_pops09/
-
- Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14. - PubMed
-
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous